First-in-class investigational therapeutic shows early promise for lymphoma patients
Pevonedistat is a first-in-class, investigational small-molecule inhibitor of the NEDD8-activating enzyme, explained Shah. "This enzyme is part of the ubiquitin-proteasome system, which is the target of a number of FDA-approved ...
Nov 11, 2015
0
22